GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » 5-Year Yield-on-Cost %

Sientra (Sientra) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sientra 5-Year Yield-on-Cost %?

Sientra's yield on cost for the quarter that ended in Sep. 2023 was 0.00.


The historical rank and industry rank for Sientra's 5-Year Yield-on-Cost % or its related term are showing as below:



SIENQ's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.13
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Sientra's 5-Year Yield-on-Cost %

For the Medical Devices subindustry, Sientra's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sientra's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Sientra's 5-Year Yield-on-Cost % falls into.



Sientra 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Sientra is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Sientra  (OTCPK:SIENQ) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Sientra 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Sientra's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (Sientra) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.
Executives
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes director, officer: President and CEO 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F. director 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett officer: General Counsel and VP 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg director 420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole director C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller officer: VP, Controller and Interim CFO
Paul Sean Little officer: Chief Financial Officer SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent director 1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines director, 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison director C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054

Sientra (Sientra) Headlines

From GuruFocus

Q2 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2018 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024